PDCD1 and lymphoma: CD20 monoclonal antibody and BTK inhibitor are the most commonly tested targeted drugs, and anti-PD-1 monoclonal antibody and CAR-T cell therapy have emerged as a new force for clinical trials of lymphoma in mainland China.